NNNN — Anbio Biotechnology Share Price
Last trade - 00:00- $7.33bn
- $7.31bn
- $8.19m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 426.11 | ||
| Price to Tang. Book | 426.11 | ||
| Price to Free Cashflow | 3,521.22 | ||
| Price to Sales | 894.97 | ||
| EV to EBITDA | 3,665.36 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.61% | ||
| Return on Equity | 14.83% | ||
| Operating Margin | 24.38% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 4.43 | 23.54 | 6.71 | 8.19 | n/a | n/a | 22.72% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +294.84 | -77.49 | +6.51 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Anbio Biotechnology is a Germany-based company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products encompasses solutions for various applications, including over-the-counter (OTC) utilization, point-of-care (POCT) settings, and laboratory applications. The Company's product detects biomarkers associated with medical domains. These domains encompasses infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. In addition, the Company's IVD products are in line with multiple sample collection matrices, including serum, plasma, whole blood, feces, urine, and saliva, for both healthcare providers and patients. Its primary research and development activities for all IVD products includes Biomarker Discovery and Validation, Assay Development, Validation - Clinical and Analytical and Platform Transfer.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 27th, 2021
- Public Since
- February 19th, 2025
- No. of Employees
- 27
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 143,891,200
- Address
- Friedrich-Ebert-Anlage 49, FRANKFURT AM MAIN, 60308
- Web
- https://anbiobiotechnology.com/
- Phone
- Auditors
- /s/ YCM CPA, Inc
Upcoming Events for NNNN
Similar to NNNN
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Beta Bionics
NASDAQ Global Market
FAQ
As of Today at 19:16 UTC, shares in Anbio Biotechnology are trading at $50.91. This share price information is delayed by 15 minutes.
Shares in Anbio Biotechnology last closed at $50.91 and the price had moved by over the past 365 days. In terms of relative price strength the Anbio Biotechnology share price has matched the S&P500 Index by over the past year.
There is no consensus recommendation for this security.
Find out moreAnbio Biotechnology does not currently pay a dividend.
Anbio Biotechnology does not currently pay a dividend.
Anbio Biotechnology does not currently pay a dividend.
To buy shares in Anbio Biotechnology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $50.91, shares in Anbio Biotechnology had a market capitalisation of $7.33bn.
Here are the trading details for Anbio Biotechnology:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: NNNN
Based on an overall assessment of its quality, value and momentum Anbio Biotechnology is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Anbio Biotechnology. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $50.91, shares in Anbio Biotechnology were trading +174.36% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Anbio Biotechnology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $50.91.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Anbio Biotechnology's directors